More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
The BPaLM regimen, which consists four-drug combination – Bedaquiline, Pretomanid, Linezolid and Moxifloxacin, has been proven to be safe, more effective and a quicker treatment option than the previous MDR-TB treatment procedure
He has more than 285 publications with 7,600 citations, 80 students have already been awarded Ph. D. degree under his able guidance and 20 postdoctoral associates have worked in his group
At present 18 per cent of the local pharmaceutical market is under government's price control
Subscribe To Our Newsletter & Stay Updated
